Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more) Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Zai Lab Ltd ZLAB

Healthcare Biotechnology
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment... see more

Current News (NDAQ:ZLAB)

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

Business Wire 8 days ago

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 13, 2026

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO(TM) (repotrectinib) for Patients with NTRK-Positive Solid Tumors

Business Wire January 6, 2026

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2026

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

Business Wire December 23, 2025

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

Business Wire December 8, 2025

Zai Lab Announces Updates to China's National Reimbursement Drug List

Business Wire December 7, 2025

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates

Business Wire November 6, 2025

Zai Lab Announces Participation in Investor Conferences in November and December 2025

Business Wire October 31, 2025
View More News ››

Opinion & Analysis (NDAQ:ZLAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ZLAB)

Zai Lab Limited: A Promising Biotech Player Poised for Signi

http://beyondspx.com/2024/08/02/zai-lab-limited-a-promising-biotech-player-poised-for-significant-growth/
MikeTester - August 3, 2024
View more Bullboard ››

North Peak Resources Ltd.

North Peak Resources Ltd.

North Peak Resources Ltd. operates as a gold exploration and development company. The company’s flagship project is the ...
View More »

Podcasts